From the boardroom to the basketball court
Growing up, dinner table conversations at our house weren't just about what we learned at school that day. My mom, Jill, was a CEO for my entire life, leading a nonprofit that made meaningful community impact while she simultaneously raised a family. Our dinner conversations included recaps of board meetings, talk of juggling multiple personal and professional roles, and advice for her kid (me!) on how to do right by others.
My mother's daily examples of leadership showed me that career success and personal fulfillment don't compete with each other—they're complementary. Now, as I help lead Guild's efforts, partnering with companies to invest in employee career development and talent pipelines, those early lessons continue to guide me.
It is possible to find balance
My mom taught me important lessons about balance that I use today. First, she taught me that having a meaningful career and making a positive impact aren't mutually exclusive. People talk about 'doing well by doing good' as an abstract concept, but I saw it firsthand every day. There was never a doubt in my mind that I would pursue the same.
I was also lucky enough to have a role model who showed it was possible to have both a thriving professional and personal life. Being a wife, mother, a (literal) boss, and an engaged community member were identities she wove together. It wasn't always easy, but watching her showed me that these identities were equally important for fulfillment.
Often people—especially women—are presented with binary choices: Career or children? Devoted partner or independent social life? Many grapple with these decisions, but we don't have to. There isn't any shame in prioritizing one thing over another one day, and changing the next. My mom taught me not to feel guilty about this balancing act.
This ripple effect of positive modeling extends beyond the family. I've seen it through stories of Guild learners, like Sherry from Oklahoma, who works at Tyson Foods. Sherry finished high school, got promoted to plant manager, and became an advocate for our program among her colleagues. She's an example of how leaders can effectively balance everything important to them: career, family, community outreach, and learning.
It's never too late (or early!) to start a second act
My mom grew up in the 1950s and 60s with three brothers and limited resources. She was a natural athlete, but didn't have the privilege of formal training in her earlier years.
Decades into adulthood, as her career entered its final chapters and she had more free time, she embraced the transition to her next chapter in life. At 50, she started playing senior women's basketball. Fast forward 25 years, and she's now a multi-titled senior Olympian at 75. Some of her best friends came through basketball, and she serves as a board member and advocate for senior women's sports.
My mom taught me that building skills later in life is more than fulfilling—it keeps you young! It increases cognitive function, improves memory, and enhances emotional well-being. There's urgency here on a global scale, as the half-life of professional skills is less than 5 years (less than 2.5 years in technology fields). The workforce needs people willing to be nimble and adapt to the skills their field requires, just as our personal lives benefit from constant learning. We can take lessons from people who grew to be the best in their field, too. Vera Wang designed her first dress at 40, and Toni Morrison wrote her first novel after a long career in publishing.
I've been inspired by people who pivot, learn, and succeed, and my admiration for people with this skill absolutely bleeds into the workplace. I like to bet on potential and give people opportunities beyond what their experience suggests, with faith that lifelong learners can figure things out with the right mindset and support. I believe that most career paths aren't linear, and I have benefited from this myself, like in a previous role. A cofounder was the first person to really take a chance on me. He truly let me run by giving me a role that, on paper, wasn't congruent with my experience but leveraged my skills in a meaningful way.
You're a role model—whether you know it or not
Another lesson I learned from my mom is something I observed from her actions, not something she intended to share. She was, and is, a role model to me and many others without asking for the title. She modeled behavior, like taking initiative on difficult problems, championing innovation, or methodically pursuing ambitious goals, that those around her naturally emulated.
I'm again reminded of Sherry from Tyson, who not only completed her own education and rose through the ranks, but then supported her husband as he continued his education. Her son now works at Tyson too, and is pursuing his degree simultaneously. Her drive to better herself was contagious and positively impacted her family's trajectory.
Other high-achievers come to mind as natural role models, too. Take four-time Paralympian Matt Stutzman, who competed in the recent Paralympics for archery. He's using the same drive that took him to Paris to pursue a career transition that will support him and his family post-games. The examples are endless.
It takes courage to take on new challenges or champion change, especially when countering established norms. Whether pitching a fresh approach to customer research or volunteering to test a new platform, lifelong learners blaze trails for others to follow, and we have the power to be those leaders for others.
Your continuous growth will have a ripple effect on others
The most powerful lesson from my mother's journey—from CEO to senior Olympian—is that our growth journeys create ripples far beyond our own lives. When we commit to continuous learning and development, we become living examples of what's possible.
For business leaders, this means investing in growth while creating cultures where employee development is prioritized. For professionals at any career stage, it means embracing opportunities that stretch you beyond your comfort zone. For parents, it means focusing your energy where it's needed most—at the boardroom or dinner table.
The result? More resilient organizations are populated by adaptable individuals who find deeper fulfillment in both personal and professional realms. More importantly, you'll inspire others along the way—perhaps even your own children, who might someday write about the dinner table lessons that shaped their leadership journey.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
37 minutes ago
- Yahoo
2 Biotech Stocks to Buy Before They Soar 84% and 240%, According to Certain Wall Street Analysts
These biotech companies have several catalysts ahead -- and in the past have soared on good news. They both offer innovative candidates that could result in game-changing treatments for patients. 10 stocks we like better than Viking Therapeutics › If you're looking to add growth to your portfolio, biotech stocks can be a great choice. Exciting research is happening in these companies' labs, and in some cases, game-changing treatment candidates are approaching important milestones or even going over the finish line. As an investor in these companies, you can benefit as they report positive clinical trial news, score a regulatory approval, or start generating product revenue. Wall Street considers two candidates extremely compelling right now, with forecasts for potential gains of more than 80% and 200% in the coming 12 months. One of these players is working in the high-growth area of weight loss drugs, and the other candidate showed its strengths by winning the world's first-ever approval of a product based on CRISPR gene editing. Let's check out these two biotech stocks to buy before they skyrocket. Viking Therapeutics (NASDAQ: VKTX) soared early last year when it reported strong data from the phase 2 trial of its weight loss candidate, VK2735, but the stock has since given back those gains and is trading closer to the level it was at prior to that data announcement. Since, the company has continued to advance VK2735 in injectable form and a version in pill form, and demand for these sorts of drugs remains high -- these are two reasons to believe that Viking has the potential to take off again. And catalysts may be on the horizon. The drug works in a manner similar to Eli Lilly's blockbuster tirzepatide, sold under the names Mounjaro and Zepbound. These drugs interact with hormones involved in digestion and have helped people quickly and safely lose weight. Viking is beginning the phase 3 trial for injectable VK2735 in the second quarter and expects data from its phase 2 trial of the pill version in the second half. Any data announcements could result in big moves for the stock, as there is plenty of room for a new company to enter the weight loss drug market -- one forecast to approach $100 billion in a few years. Wall Street is optimistic about Viking's prospects, with the average price forecast predicting an increase of about 240% in the stock price from today's level. Of course, Viking depends heavily on the outcome of these trials, so some risk is involved -- but data have been strong, so growth investors may want to get in on Viking now to potentially post a big win later. CRISPR Therapeutics (NASDAQ: CRSP) stock surged in the year leading up to a major milestone: its first product approval. But since last year's launch of Casgevy, a gene-editing treatment for blood disorders, the stock has been on the decline. Sometimes, investors buy a stock well before the company wins approval or launches a product, then lock in gains after the good news lands -- and I think this is what's happened here. But what this does is offer us a chance to get in at a very good price on a promising company that could deliver fantastic news down the road. Casgevy, as a gene-editing treatment, requires a longer time to roll out than a pill or injection, as it includes several steps that happen over a period of months. The company recently said new patient initiations should increase "significantly" this year -- so there's reason to be optimistic about revenue growth ahead. CRISPR Therapeutics also recently reported positive phase 1 data for a gene editing candidate addressing the problem of high cholesterol. And the company expects to report data soon from a phase 1 trial of a candidate targeting patients with elevated levels of lipoprotein(a) -- a risk factor for cardiovascular events. These could represent huge markets for CRISPR Therapeutics if the candidates reach the finish line, and in the meantime, any potential positive news could boost the stock. The company also expects other trial updates in candidates for oncology and autoimmune diseases this year -- so this biotech's calendar is full of possible catalysts. Wall Street's average price forecast calls for an 84% gain for CRISPR Therapeutics from today's price -- if all goes well in clinical trials and Casgevy starts to show revenue growth, now could represent a golden buying opportunity for growth investors. Before you buy stock in Viking Therapeutics, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and Viking Therapeutics wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $664,089!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $881,731!* Now, it's worth noting Stock Advisor's total average return is 994% — a market-crushing outperformance compared to 172% for the S&P 500. Don't miss out on the latest top 10 list, available when you join . See the 10 stocks » *Stock Advisor returns as of June 9, 2025 Adria Cimino has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends CRISPR Therapeutics. The Motley Fool recommends Viking Therapeutics. The Motley Fool has a disclosure policy. 2 Biotech Stocks to Buy Before They Soar 84% and 240%, According to Certain Wall Street Analysts was originally published by The Motley Fool Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
40 minutes ago
- Yahoo
Dan Ives Says Market Is 'Massively Underestimating' This AI Play, Urges Investors To Look Beyong Mag 7
Benzinga and Yahoo Finance LLC may earn commission or revenue on some items through the links below. Dan Ives' new artificial intelligence exchange-traded fund (ETF) holds securities beyond the Magnificent 7 stocks, as he believes in looking past valuations for investments in the technology sector. What Happened: The Dan IVES Wedbush AI Revolution ETF (NYSE:IVES), managed by the Wedbush analyst, started trading on June 4, earlier this month. Ives boasts of the fund by saying that it just doesn't have the top four, five Magnificent 7 names, but stocks which investors wouldn't even thematically consider as an AI name today. "I believe the market is still massively underestimating what the growth is going to look like for the AI revolution in tech," he told CNBC. Trending: Maker of the $60,000 foldable home has 3 factory buildings, 600+ houses built, and big plans to solve housing — According to him, tech trade remains significant even for the investors who missed out on its growth in the past few years. "If you focus just on valuation, you miss every transformational tech stock of the last 20 years," Ives said. Ives says Oracle Corp. (NYSE:ORCL) will be the 'epicenter' of the AI theme, while highlighting other 'AI 30' stocks which are part of his fund. Palantir Technologies Inc. (NASDAQ:PLTR), International Business Machines Corp. (NYSE:IBM), Salesforce Inc. (NYSE:CRM), SoundHound AI Inc. (NASDAQ:SOUN), and Innodata Inc. (NASDAQ:INOD) are a few notable names that are a part of his ETF's 'AI 30' basket. Microsoft Corp. (NASDAQ:MSFT), Nvidia Corp. (NASDAQ:NVDA), and Broadcom Inc. (NASDAQ:AVGO) are the top three holdings of the IVES It Matters: The 'AI 30' stocks, which are a part of the IVES ETF, hold the AI plays from multiple industries. They include hyperscalers, cybersecurity, consumer platforms, and robotics. According to Ives, the list was compiled from his deep dives into major AI players. The ETF has $183 million in assets under management as of June 17 close. Ives said that the AI space was experiencing a "golden age." The Dan IVES Wedbush AI Revolution ETF has risen by 2.76% since its inception. A comparable index, S&P Kensho Global Artificial Intelligence Enablers, rose 6.08% on a month-to-date basis. Meanwhile, the SPDR S&P 500 ETF Trust (NYSE:SPY) and Invesco QQQ Trust ETF (NASDAQ:QQQ), which track the S&P 500 index and Nasdaq 100 index, respectively, declined slightly on Wednesday. The SPY was down 0.015% at $597.44, while the QQQ was 0.017% lower at $528.99, according to Benzinga Pro data. Read Next: Invest early in CancerVax's breakthrough tech aiming to disrupt a $231B market. Back a bold new approach to cancer treatment with high-growth potential. If there was a new fund backed by Jeff Bezos offering a 7-9% target yield with monthly dividends would you invest in it? Photo courtesy: Shutterstock This article Dan Ives Says Market Is 'Massively Underestimating' This AI Play, Urges Investors To Look Beyong Mag 7 originally appeared on
Yahoo
an hour ago
- Yahoo
Christina Bohannan makes third run for Iowa's 1st Congressional District
Jun. 21—History shows that just because a candidate makes multiple attempts to win an election doesn't mean they can't eventually pull through. U.S. Rep. Mariannette Miller-Meeks lost a number of times to Dave Loebsack before winning Iowa's 1st Congressional District seat in a close 2020 election. Now her past Democratic challenger, Christina Bohannan, is attempting the same thing for the 2026 election cycle, provided she is the favorite in the primary. On June 17, Bohannan announced her campaign to take on Miller-Meeks once again. In a press release, her campaign said Bohannan nearly defeated Miller-Meeks in 2024 — less than 800 votes decided the election — and that the Democrat "outworked, outraised and outmatched her." Bohannan said, "Mariannette Miller-Meeks has had three terms in Congress — three chances to do right by the people of Iowa. Instead, she has taken over $4 million from corporate special interests and done nothing but vote their way. And she has put partisan politics over Iowans again and again. From cutting billions of dollars from Medicaid in the Trump Administration's One Big Beautiful Bill, to siding with DOGE's cuts to Social Security and enabling unelected, unaccountable billionaires like Elon Musk, Bohannan said the Republican congresswoman has forgotten about her constituents. "It's time someone put Iowa first," Bohannan said. Bohannan went on to say Miller-Meeks needs to explain "why she keeps putting Washington special interests first." The Democratic challenger claimed Miller-Meeks supported Trump's One Big Beautiful Bill, repeatedly voted for cost-increasing tariffs and is a member of the DOGE Caucus. Bohannan previously worked as an engineer and taught at the University of Iowa College of Law for 20 years. She also worked as an elected legislator for the Iowa House, defeating a 20-year incumbent in District 85. Bohannan is running for Congress because she believes in a government that works for the people. In May, another Democrat announced he would be running for Iowa's 1st Congressional District. Bob Krause, a former legislator who also tried running for U.S. Senate, announced his campaign with the slogan "Flip The House With Krause." Krause said Miller-Meeks votes "like Trump's rubber stamp." Travis Terrell, a Democrat from Johnson County, also announced his bid for Iowa's 1st Congressional District race. His campaign page on Facebook notes he is a working-class, New Deal Democrat fighting for healthcare, fair wages and a government that serves other working-class people and not billionaires. In addition to Miller-Meeks likely running for the seat, fellow Republican and former primary challenger David Pautsch announced in February that he would also be running for the seat. Pautsch touts himself as a MAGA Republican. He has been critical of Miller-Meeks, saying she is not conservative enough.
